{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:17:03Z","timestamp":1778555823281,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejphar.2017.10.012","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T22:22:48Z","timestamp":1507846968000},"page":"2-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Als and Ftd: Insights into the disease mechanisms and therapeutic targets"],"prefix":"10.1016","volume":"817","author":[{"given":"Rajka M.","family":"Liscic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejphar.2017.10.012_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00401-011-0911-2","article-title":"P62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND\/ALS","volume":"122","author":"Al-Sarraj","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.10.012_bib2","article-title":"Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development","author":"Boxer","year":"2012","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.012_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00401-014-1299-6","article-title":"TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord","volume":"128","author":"Brettschneider","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.ejphar.2017.10.012_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"10.1016\/j.ejphar.2017.10.012_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.adgen.2015.07.001","article-title":"Functional significance of TDP-43 mutations in disease","volume":"91","author":"Buratti","year":"2015","journal-title":"Adv. Genet"},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.012_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","article-title":"Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for frontotemporal lobar degeneration","volume":"114","author":"Cairns","year":"2007","journal-title":"Acta Neuropathol."},{"issue":"11","key":"10.1016\/j.ejphar.2017.10.012_bib7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.ejphar.2017.10.012_bib8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2017.10.012_bib9","article-title":"Motor function and behaviour across the ALS-FTD spectrum","author":"De Silva","year":"2015","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.ejphar.2017.10.012_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.ejphar.2017.10.012_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14737175.2015.1034108","article-title":"Motor neuron disease-frontotemporal dementia: a clinical continuum","volume":"15","author":"Devenney","year":"2015","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.012_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2014.07.037","article-title":"Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion","volume":"36","author":"Fratta","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.ejphar.2017.10.012_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.21344","article-title":"TDP-43 A315T mutation in familial motor neuron disease","volume":"63","author":"Gitcho","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2017.10.012_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-015-0204-4","article-title":"Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau","volume":"3","author":"Hochgrafe","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.012_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1212\/01.WNL.0000078928.20107.52","article-title":"Survival in frontotemporal dementia","volume":"61","author":"Hodges","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.10.012_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s40478-014-0166-y","article-title":"A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD","volume":"2","author":"Hukema","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.ejphar.2017.10.012_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1172\/JCI44867","article-title":"Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice","volume":"121","author":"Igaz","year":"2011","journal-title":"J. Clin. Invest"},{"issue":"6","key":"10.1016\/j.ejphar.2017.10.012_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nrneurol.2015.65","article-title":"FTD and ALS--translating mouse studies into clinical trials","volume":"11","author":"Ittner","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.ejphar.2017.10.012_bib19","doi-asserted-by":"crossref","first-page":"e100230","DOI":"10.1371\/journal.pone.0100230","article-title":"Ceftriaxone preserves glutamate transporters and prevents intermittent hypoxia-induced vulnerability to brain excitotoxic injury","volume":"9","author":"Jagadapillai","year":"2014","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.012_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2013.08.003","article-title":"The role of heat shock proteins in amyotrophic lateral sclerosis: the therapeutic potential of arimoclomol","volume":"141","author":"Kalmar","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"5918","key":"10.1016\/j.ejphar.2017.10.012_bib21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.1166066","article-title":"Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis","volume":"323","author":"Kwiatkowski","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ejphar.2017.10.012_bib22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cell.2009.03.006","article-title":"Rethinking ALS: the FUS about TDP-43","volume":"136","author":"Lagier-Tourenne","year":"2009","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.012_bib23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","article-title":"Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis","volume":"79","author":"Ling","year":"2013","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.ejphar.2017.10.012_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/aiht-2015-66-2679","article-title":"Molecular basis of ALS and FTD: implications for translational studies","volume":"66","author":"Liscic","year":"2015","journal-title":"Arh. Hig. Rada Toksikol."},{"issue":"2","key":"10.1016\/j.ejphar.2017.10.012_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pnpbp.2010.07.017","article-title":"Molecular basis of amyotrophic lateral sclerosis","volume":"35","author":"Liscic","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.ejphar.2017.10.012_bib26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1468-1331.2008.02195.x","article-title":"ALS and FTLD: two faces of TDP-43 proteinopathy","volume":"15","author":"Liscic","year":"2008","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.ejphar.2017.10.012_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","article-title":"Incidence of amyotrophic lateral sclerosis in Europe","volume":"81","author":"Logroscino","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.ejphar.2017.10.012_bib28","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.59.7.1077","article-title":"The overlap of amyotrophic lateral sclerosis and frontotemporal dementia","volume":"59","author":"Lomen-Hoerth","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejphar.2017.10.012_bib29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1212\/01.WNL.0000055861.95202.8D","article-title":"Are amyotrophic lateral sclerosis patients cognitively normal?","volume":"60","author":"Lomen-Hoerth","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.10.012_bib30","doi-asserted-by":"crossref","first-page":"Suppl, 38","DOI":"10.1016\/0022-510X(94)90175-9","article-title":"New pathological findings in amyotrophic lateral sclerosis","volume":"124","author":"Lowe","year":"1994","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.012_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.expneurol.2009.08.007","article-title":"Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial","volume":"223","author":"Mazzini","year":"2010","journal-title":"Exp. Neurol."},{"issue":"19","key":"10.1016\/j.ejphar.2017.10.012_bib32","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.wnl.0000334277.16896.fa","article-title":"Incidence of early-onset dementias in Cambridgeshire, United Kingdom","volume":"71","author":"Mercy","year":"2008","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejphar.2017.10.012_bib33","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1212\/WNL.52.7.1311","article-title":"practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology: ALS practice parameters task force","volume":"52","author":"Miller","year":"1999","journal-title":"Neurology"},{"issue":"6201","key":"10.1016\/j.ejphar.2017.10.012_bib34","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1126\/science.1256800","article-title":"C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins","volume":"345","author":"Mizielinska","year":"2014","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejphar.2017.10.012_bib35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/WCO.0000000000000130","article-title":"C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function?","volume":"27","author":"Mizielinska","year":"2014","journal-title":"Curr. Opin. Neurol."},{"issue":"5796","key":"10.1016\/j.ejphar.2017.10.012_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2017.10.012_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/nyas.12638","article-title":"Frontotemporal dementia: a bridge between dementia and neuromuscular disease","volume":"1338","author":"Ng","year":"2015","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.012_bib38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1534\/genetics.113.156570","article-title":"Highly efficient targeted mutagenesis in mice using TALENs","volume":"195","author":"Panda","year":"2013","journal-title":"Genetics"},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.012_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00441-012-1432-6","article-title":"The role of Nogo-A in axonal plasticity, regrowth and repair","volume":"349","author":"Pernet","year":"2012","journal-title":"Cell Tissue Res"},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.012_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaneurol.2015.4321","article-title":"Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1\/2 and 2a clinical trials","volume":"73","author":"Petrou","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2017.10.012_bib41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fncel.2015.00414","article-title":"The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"9","author":"Radford","year":"2015","journal-title":"Front Cell Neurosci."},{"issue":"2","key":"10.1016\/j.ejphar.2017.10.012_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.012_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(14)70233-9","article-title":"C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol."},{"issue":"6415","key":"10.1016\/j.ejphar.2017.10.012_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejphar.2017.10.012_bib45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s13311-015-0338-x","article-title":"TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets","volume":"12","author":"Scotter","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"5870","key":"10.1016\/j.ejphar.2017.10.012_bib46","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.1154584","article-title":"TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis","volume":"319","author":"Sreedharan","year":"2008","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ejphar.2017.10.012_bib47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17482960802372371","article-title":"The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis","volume":"9","author":"Strong","year":"2008","journal-title":"Amyotroph. Lateral Scler."},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.012_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17482960802654364","article-title":"Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis","volume":"10","author":"Strong","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"issue":"5","key":"10.1016\/j.ejphar.2017.10.012_bib49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0b013e3181ccc732","article-title":"Genetic contribution of FUS to frontotemporal lobar degeneration","volume":"74","author":"Van Langenhove","year":"2010","journal-title":"Neurology"},{"issue":"5918","key":"10.1016\/j.ejphar.2017.10.012_bib50","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ejphar.2017.10.012_bib51","doi-asserted-by":"crossref","first-page":"e91608","DOI":"10.1371\/journal.pone.0091608","article-title":"Dexpramipexole is ineffective in two models of ALS related neurodegeneration","volume":"9","author":"Vieira","year":"2014","journal-title":"Plos One"},{"issue":"44","key":"10.1016\/j.ejphar.2017.10.012_bib52","doi-asserted-by":"crossref","first-page":"18809","DOI":"10.1073\/pnas.0908767106","article-title":"TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration","volume":"106","author":"Wegorzewska","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.ejphar.2017.10.012_bib53","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1073\/pnas.0912417107","article-title":"TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration","volume":"107","author":"Wils","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.012_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/path.4043","article-title":"Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice","volume":"228","author":"Wils","year":"2012","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.ejphar.2017.10.012_bib55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0896-6273(95)90259-7","article-title":"An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria","volume":"14","author":"Wong","year":"1995","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.012_bib56","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1073\/pnas.1013343108","article-title":"Non-ATG-initiated translation directed by microsatellite expansions","volume":"108","author":"Zu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917306623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917306623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:48:57Z","timestamp":1719514137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917306623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":56,"alternative-id":["S0014299917306623"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.012","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Als and Ftd: Insights into the disease mechanisms and therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}